Akorn, Natco sign agreement to market anti-nausea drugs

By Elaine Rigoli

Tampa, Fla., March 28 - Akorn, Inc. and Natco Pharma Ltd. have signed a purchase and supply agreement to commercialize two oral drug products for cancer patients suffering from nausea and vomiting.

The products will focus on the anti-nausea market and have a current market size of about $800 million, according to a news release.

Natco will be responsible for the development and manufacturing of both drug products, while Akorn will be responsible for marketing and distribution in the hospital, clinic and home health care markets in the United States and Canada, the release said.

Buffalo Grove, Ill.-based Akorn manufactures and markets sterile specialty pharmaceuticals.

Hyderabad, India-based Natco is an integrated pharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.